Insider files Hyliion (HYLN) Form 144 for 31,105-share sale
Rhea-AI Filing Summary
Hyliion Holdings (HYLN) insider activity is disclosed in a Form 144 notice covering a planned sale of restricted stock. The notice reports an intention to sell 31,105 shares of common stock through UBS Financial Services Inc. on the NYSE, with an aggregate market value of 51,600 and total shares outstanding of 175,974,228. The securities were acquired on 09/15/2025 in an employee benefit transaction from Hyliion Holdings, with the purchase price paid in cash. The seller also previously sold 3,357 common shares on 09/02/2025 for gross proceeds of 5,362. The signer represents that they are not aware of any undisclosed material adverse information about Hyliion’s current or prospective operations.
Positive
- None.
Negative
- None.
FAQ
How many Hyliion (HYLN) shares are covered by this Form 144 notice?
The Form 144 notice covers an intended sale of 31,105 shares of Hyliion common stock through UBS Financial Services Inc. on the NYSE.
What is the aggregate market value of the Hyliion (HYLN) shares to be sold?
The aggregate market value of the 31,105 common shares to be sold is reported as 51,600.
When were the Hyliion (HYLN) shares acquired and how?
The common shares were acquired on 09/15/2025 in an employee benefit transaction from Hyliion Holdings, with the purchase price paid in cash.
What is the approximate sale date and exchange for these Hyliion (HYLN) shares?
The notice lists an approximate date of sale of 11/17/2025, with the shares expected to be sold on the NYSE through UBS Financial Services Inc.
How many Hyliion (HYLN) shares are outstanding according to this notice?
The Form 144 reports that 175,974,228 shares of Hyliion common stock are outstanding.
Has the seller recently sold other Hyliion (HYLN) shares?
Yes. The seller previously sold 3,357 common shares on 09/02/2025 for gross proceeds of 5,362.
What representation does the seller make about Hyliion (HYLN) in this Form 144?
The seller represents that they do not know any material adverse information about Hyliion’s current or prospective operations that has not been publicly disclosed.